Clinical Trial

Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 29, 2025 (before its estimated January 6, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-center, open-label, single-arm, dose-escalation trial. The aim of this study is to investigate the safety and efficacy of Anti-CD19 IL-10/IL15 CAR-NK cells in patients with refractory/relapsed autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myositis, ANCA associated vasculitis, sjogren syndrome, and antiphospholipid syndrome.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT06614270
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Systemic Sclerosis (SSc), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathy (IIM), Sjogren's Syndrome, Antiphospholipid Syndrome, Systemic Lupus Erythematosus
Enrollment 15 participants
Start Date 2025-01-06
Primary Completion 2026-01-06 (estimated)
Study Completion 2027-01-06 (estimated)
Updated on ClinicalTrials.gov 2025-12-29